Genesis and Affibody partner on autoimmune innovation drug ABY-035

Under the agreement, Affibody will receive a down payment of $10 million, up to $215 million in registration and sales milestone payments, as well as a sales commission in the Genesis commercialization areaGenesis will share some of the global development costs of aBY-035 and thus receive a global milestone payment and sales commission paid by AffibodyAffibody will be responsible for the production and supply of pharmaceuticals for aby-035's clinical development and commercialization worldwideABY-035 is a new fusion protein drug that inhibits leukovirus 17 and is about to complete the second phase of clinical worldwideThe ABY-035 was developed using Affibody's two original, globally patented technology platforms, "Affibody Technology Platform" and "Albumod Technology Platform"Affibody is a new protein drug platform with a relatively high affinity and lower molecular weight compared to conventional antibody drugs, and has an extremely wide range of commercial applicationsThe Albumod technology platform can significantly increase the half-life of Affibody drugs in the body, thus achieving a drug cycle similar to that of antibody drugsThanks to the advantages of these two technology platforms, The ABY-035 is expected to be the best-of-the-class product of the interleukin 17 familyPatients are expected to be treated at home by subcutaneous injections, with a significant reduction in the number of needles injected, and a significant reduction in the cost of producing per dose because ABY-035 is produced in EcoliABY-035 shows excellent efficacy and safety in the upcoming Phase II psoriasis clinical trialGenesis has extensive clinical development experience in the field of immunopharmaceuticals, bringing to the Chinese, U.Sand European markets a number of macromolecule drugs for leukin 17, leukocyte 1, leukocyte 6, T lymphocytes and B lymphocytesGenesis will work with Affibody on a number of global multicenter clinical trialsIn both indications, Genesis will dominate the clinical strategy and specific operations of global registrations(Cuts in the original text)